National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

Baker Norton Pharmaceuticals, Inc.

Liliane J Striker

Gary E Striker

Fred P Sherman

Emmanuel Peten

The state of the extracellular matrix of discrete tissue subsegments can be determined via an approach that combines microdissection, reverse transcription and polymerase chain reaction. Using this approach, a positive correlation between a fibrotic condition and alterations in messenger RNA levels of matrix components provides the basis for (i) the diagnosis of a fibrotic disease and (ii) the monitoring of the efficacy of a therapeutic regimen.

Quantification of indicators of fibrosis

A method of treating a mammalian patient suffering from a chronic progressive vascular disease (CPVD) characterized by scarring and/or fibrosis to halt the progress of the disease and cause resolution of already-formed scarring or fibrotic lesions. The method consists of the administration to the patient of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred, with total daily dosage of PPS or PPS salt ranging from about 50 to 1200 mg per day.

Growing community of inventors

Bethesda, MD, United States of America

Liliane J Striker